AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Intel cancels Intel Capital spinoff as Lip-Bu Tan shifts to financial discipline
2
Adam Neumann’s Flow raises over $100M at $2.5B valuation
3
Intel’s AI reset highlights hard lessons from Israeli acquisitions
4
Inside the Intel reckoning: layoffs, leadership, and the long road back to relevance
5
Intel employees left in the dark amid talk of radical transformation
More news

Mori Arkin

5 stories about Mori Arkin
default image

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
default image

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani
Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
סטפן אושמן מנכ"ל Merck

Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel

20.02.18|Meir Orbach
The incubator program has a five year budget of 20 million euros
default image

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
default image

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year